Chemists at Scripps Research have redesigned fentanyl's molecular structure to create a safer version that maintains pain relief while dramatically reducing respiratory depression. The modified compound, featuring a novel 2-azaspiro[3.3]heptane core structure, showed no detectable recruitment of the beta-arrestin pathway that contributes to dangerous side effects.

Published in ACS Medicinal Chemistry Letters on January 22, 2026, the research addresses the opioid crisis that claimed more than 70,000 U.S. lives in 2023. Kim D. Janda, the Ely R. Callaway Jr. Professor of Chemistry at Scripps Research, led the team that used bioisosteric replacement to swap fentanyl's central ring structure while preserving its analgesic properties.

The redesigned molecule left the body quickly with a half-life of approximately 27 minutes and caused slowed breathing only at very high doses, with breathing returning to normal within 25-30 minutes. This short-acting profile could be beneficial in controlled medical settings. The team plans to leverage this discovery to develop new opioid patent-free vaccines that train the immune system to recognize and neutralize fentanyl molecules before they reach the brain.